| Literature DB >> 24657240 |
C Caselli1, A D'Amico2, M Cabiati3, T Prescimone3, S Del Ry3, D Giannessi3.
Abstract
Cardiovascular disease (CVD) is the leading cause of death worldwide and the prevalence of obesity and diabetes are increasing. In obesity, adipose tissue increases the secretion of bioactive mediators (adipokines) that may represent a key mechanism linking obesity to CVD. Adiponectin, extensively studied in metabolic diseases, exerts anti-diabetic, anti-atherogenic and anti-inflammatory activities. Due to these positive actions, the role of adiponectin in cardiovascular protection has been evaluated in recent years. In particular, for its potential therapeutic benefits in humans, adiponectin has become the subject of intense preclinical research. In the cardiovascular context, understanding of the cellular and molecular mechanisms underlying the adiponectin system, throughout its secretion, regulation and signaling, is critical for designing new drugs that target adiponectin system molecules. This review focused on recent advances regarding molecular mechanisms related to protective effects of the adiponectin system on both cardiac and vascular compartments and its potential use as a target for therapeutic intervention of CVD.Entities:
Keywords: Adiponectin; Adiponectin system; Cardiovascular protection; Therapeutic target
Mesh：
Substances：
Year: 2014 PMID： 24657240 DOI： 10.1016/j.phrs.2014.03.003
Source DB: PubMed Journal: Pharmacol Res ISSN： 1043-6618 Impact factor: 7.658